Vaxart, Inc. (VXRT)
USD 0.29
(-12.84%)
USD 0.29
(-12.84%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 7.37 Million USD | 6796.26% |
| 2022 | 107 Thousand USD | -88.0% |
| 2021 | 892 Thousand USD | -77.95% |
| 2020 | 4.04 Million USD | -58.97% |
| 2019 | 9.86 Million USD | 137.12% |
| 2018 | 4.15 Million USD | -28.77% |
| 2017 | 5.83 Million USD | -34.39% |
| 2016 | 8.9 Million USD | -4.3% |
| 2015 | 9.3 Million USD | -62.2% |
| 2014 | 24.6 Million USD | -64.19% |
| 2013 | 68.7 Million USD | 104.46% |
| 2012 | 33.6 Million USD | 126.45% |
| 2011 | 14.83 Million USD | -57.61% |
| 2010 | 35 Million USD | 233.73% |
| 2009 | 10.48 Million USD | 0.0% |
| 2008 | - USD | 0.0% |
| 2007 | - USD | -100.0% |
| 2006 | 89.86 Million USD | -16.83% |
| 2005 | 108.05 Million USD | -24.0% |
| 2004 | 142.18 Million USD | -19.47% |
| 2003 | 176.57 Million USD | -9.9% |
| 2002 | 195.96 Million USD | -16.55% |
| 2001 | 234.82 Million USD | 2.64% |
| 2000 | 228.78 Million USD | -2.06% |
| 1999 | 233.6 Million USD | -3.91% |
| 1998 | 243.1 Million USD | 6.3% |
| 1997 | 228.7 Million USD | -4.67% |
| 1996 | 239.9 Million USD | 18.76% |
| 1995 | 202 Million USD | 22.65% |
| 1994 | 164.7 Million USD | 62.11% |
| 1993 | 101.6 Million USD | 23.3% |
| 1992 | 82.4 Million USD | 20.82% |
| 1991 | 68.2 Million USD | -6.32% |
| 1990 | 72.8 Million USD | 22.97% |
| 1989 | 59.2 Million USD | 25.16% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 2.18 Million USD | -32.79% |
| 2024 Q2 | 6.4 Million USD | 193.49% |
| 2023 Q3 | 446 Thousand USD | -67.16% |
| 2023 Q1 | 675 Thousand USD | 2968.18% |
| 2023 Q2 | 1.35 Million USD | 101.19% |
| 2023 Q4 | 3.24 Million USD | 627.58% |
| 2023 FY | 7.37 Million USD | 6796.26% |
| 2022 Q1 | 85 Thousand USD | 14.86% |
| 2022 Q4 | 22 Thousand USD | 0.0% |
| 2022 Q3 | - USD | 0.0% |
| 2022 Q2 | - USD | -100.0% |
| 2022 FY | 107 Thousand USD | -88.0% |
| 2021 Q1 | 506 Thousand USD | 42.13% |
| 2021 Q2 | 112 Thousand USD | -77.87% |
| 2021 FY | 892 Thousand USD | -77.95% |
| 2021 Q4 | 74 Thousand USD | -63.0% |
| 2021 Q3 | 200 Thousand USD | 78.57% |
| 2020 Q1 | 2.9 Million USD | -25.89% |
| 2020 Q2 | 523 Thousand USD | -81.98% |
| 2020 Q4 | 356 Thousand USD | 34.34% |
| 2020 Q3 | 265 Thousand USD | -49.33% |
| 2020 FY | 4.04 Million USD | -58.97% |
| 2019 Q1 | 5.4 Million USD | 206.0% |
| 2019 Q2 | 85 Thousand USD | -98.43% |
| 2019 Q3 | 454 Thousand USD | 434.12% |
| 2019 Q4 | 3.91 Million USD | 762.56% |
| 2019 FY | 9.86 Million USD | 137.12% |
| 2018 Q4 | 1.76 Million USD | 528.83% |
| 2018 FY | 4.15 Million USD | -28.77% |
| 2018 Q1 | 1.5 Million USD | -44.33% |
| 2018 Q2 | 608 Thousand USD | -59.55% |
| 2018 Q3 | 281 Thousand USD | -53.78% |
| 2017 FY | 5.83 Million USD | -34.39% |
| 2017 Q3 | 100 Thousand USD | 0.0% |
| 2017 Q4 | 2.7 Million USD | 2600.0% |
| 2017 Q2 | 100 Thousand USD | -97.96% |
| 2017 Q1 | 4.9 Million USD | 28.95% |
| 2016 FY | 8.9 Million USD | -4.3% |
| 2016 Q4 | 3.8 Million USD | 3700.0% |
| 2016 Q3 | 100 Thousand USD | -80.0% |
| 2016 Q2 | 500 Thousand USD | -90.57% |
| 2016 Q1 | 5.3 Million USD | 211.76% |
| 2015 FY | 9.3 Million USD | -62.2% |
| 2015 Q4 | 1.7 Million USD | 0.0% |
| 2015 Q1 | 5.9 Million USD | -57.55% |
| 2015 Q2 | 4.1 Million USD | -30.51% |
| 2015 Q3 | 1.7 Million USD | -58.54% |
| 2014 Q3 | 700 Thousand USD | -91.67% |
| 2014 Q1 | 29.5 Million USD | 59.46% |
| 2014 Q4 | 13.9 Million USD | 1885.71% |
| 2014 FY | 24.6 Million USD | -64.19% |
| 2014 Q2 | 8.4 Million USD | -71.53% |
| 2013 Q2 | 9.25 Million USD | -25.94% |
| 2013 FY | 68.7 Million USD | 104.46% |
| 2013 Q4 | 18.5 Million USD | 50.41% |
| 2013 Q3 | 12.3 Million USD | 32.92% |
| 2013 Q1 | 12.49 Million USD | 20.32% |
| 2012 FY | 33.6 Million USD | 126.45% |
| 2012 Q2 | 631 Thousand USD | -0.16% |
| 2012 Q3 | 632 Thousand USD | 0.16% |
| 2012 Q1 | 632 Thousand USD | -24.31% |
| 2012 Q4 | 10.38 Million USD | 1543.35% |
| 2011 Q4 | 835 Thousand USD | -23.11% |
| 2011 Q1 | 9.17 Million USD | 124.83% |
| 2011 Q2 | 3.74 Million USD | -59.18% |
| 2011 Q3 | 1.08 Million USD | -70.99% |
| 2011 FY | 14.83 Million USD | -57.61% |
| 2010 Q3 | 12.33 Million USD | 154.38% |
| 2010 FY | 35 Million USD | 233.73% |
| 2010 Q4 | 4.08 Million USD | -66.92% |
| 2010 Q2 | 4.84 Million USD | -64.71% |
| 2010 Q1 | 13.74 Million USD | 31.0% |
| 2009 FY | 10.48 Million USD | 0.0% |
| 2009 Q1 | - USD | 0.0% |
| 2009 Q4 | 10.48 Million USD | 0.0% |
| 2009 Q2 | - USD | 0.0% |
| 2009 Q3 | - USD | 0.0% |
| 2008 Q4 | - USD | 0.0% |
| 2008 Q3 | - USD | 0.0% |
| 2008 Q2 | - USD | 0.0% |
| 2008 Q1 | - USD | 0.0% |
| 2008 FY | - USD | 0.0% |
| 2007 Q3 | 20.11 Million USD | -3.66% |
| 2007 Q4 | - USD | -100.0% |
| 2007 Q1 | 23.74 Million USD | -21.73% |
| 2007 Q2 | 20.87 Million USD | -12.11% |
| 2007 FY | - USD | -100.0% |
| 2006 Q4 | 30.34 Million USD | 54.54% |
| 2006 FY | 89.86 Million USD | -16.83% |
| 2006 Q3 | 19.63 Million USD | -3.63% |
| 2006 Q2 | 20.37 Million USD | 4.39% |
| 2006 Q1 | 19.51 Million USD | -22.95% |
| 2005 Q2 | 25.87 Million USD | -0.76% |
| 2005 FY | 108.05 Million USD | -24.0% |
| 2005 Q1 | 26.07 Million USD | -37.39% |
| 2005 Q4 | 25.33 Million USD | 13.21% |
| 2005 Q3 | 22.37 Million USD | -13.54% |
| 2004 Q4 | 41.64 Million USD | -4.86% |
| 2004 Q3 | 43.77 Million USD | -8.79% |
| 2004 Q1 | 46.34 Million USD | -3.39% |
| 2004 Q2 | 47.99 Million USD | 3.54% |
| 2004 FY | 142.18 Million USD | -19.47% |
| 2003 FY | 176.57 Million USD | -9.9% |
| 2003 Q4 | 47.97 Million USD | 13.06% |
| 2003 Q3 | 42.43 Million USD | 22.47% |
| 2003 Q2 | 34.64 Million USD | -32.73% |
| 2003 Q1 | 51.51 Million USD | -11.33% |
| 2002 Q4 | 58.09 Million USD | 26.02% |
| 2002 Q1 | 40.96 Million USD | -25.18% |
| 2002 Q2 | 50.8 Million USD | 24.0% |
| 2002 Q3 | 46.1 Million USD | -9.26% |
| 2002 FY | 195.96 Million USD | -16.55% |
| 2001 FY | 234.82 Million USD | 2.64% |
| 2001 Q4 | 54.76 Million USD | 0.29% |
| 2001 Q3 | 54.6 Million USD | -16.37% |
| 2001 Q2 | 65.28 Million USD | 8.49% |
| 2001 Q1 | 60.17 Million USD | -8.3% |
| 2000 Q4 | 65.62 Million USD | 31.95% |
| 2000 FY | 228.78 Million USD | -2.06% |
| 2000 Q1 | 55.84 Million USD | -5.68% |
| 2000 Q2 | 57.58 Million USD | 3.12% |
| 2000 Q3 | 49.73 Million USD | -13.62% |
| 1999 FY | 233.6 Million USD | -3.91% |
| 1999 Q4 | 59.2 Million USD | 9.23% |
| 1999 Q3 | 54.2 Million USD | -12.86% |
| 1999 Q1 | 58.02 Million USD | -10.18% |
| 1999 Q2 | 62.19 Million USD | 7.2% |
| 1998 FY | 243.1 Million USD | 6.3% |
| 1998 Q1 | 58.6 Million USD | -4.87% |
| 1998 Q2 | 61.2 Million USD | 4.44% |
| 1998 Q4 | 64.6 Million USD | 10.05% |
| 1998 Q3 | 58.7 Million USD | -4.08% |
| 1997 Q1 | 56.4 Million USD | -11.88% |
| 1997 Q3 | 52.8 Million USD | -8.81% |
| 1997 Q4 | 61.6 Million USD | 16.67% |
| 1997 FY | 228.7 Million USD | -4.67% |
| 1997 Q2 | 57.9 Million USD | 2.66% |
| 1996 FY | 239.9 Million USD | 18.76% |
| 1996 Q2 | 58.3 Million USD | -2.02% |
| 1996 Q3 | 58 Million USD | -0.51% |
| 1996 Q4 | 64 Million USD | 10.34% |
| 1996 Q1 | 59.5 Million USD | -1.65% |
| 1995 Q3 | 48.1 Million USD | 2.34% |
| 1995 Q4 | 60.5 Million USD | 25.78% |
| 1995 Q1 | 46.5 Million USD | 5.92% |
| 1995 Q2 | 47 Million USD | 1.08% |
| 1995 FY | 202 Million USD | 22.65% |
| 1994 Q2 | 41.6 Million USD | 16.85% |
| 1994 FY | 164.7 Million USD | 62.11% |
| 1994 Q4 | 43.9 Million USD | 0.92% |
| 1994 Q1 | 35.6 Million USD | 19.46% |
| 1994 Q3 | 43.5 Million USD | 4.57% |
| 1993 Q3 | 27.6 Million USD | 22.12% |
| 1993 Q4 | 29.8 Million USD | 7.97% |
| 1993 Q1 | 21.5 Million USD | -4.02% |
| 1993 Q2 | 22.6 Million USD | 5.12% |
| 1993 FY | 101.6 Million USD | 23.3% |
| 1992 Q1 | 18.1 Million USD | -1.63% |
| 1992 Q4 | 22.4 Million USD | 2.28% |
| 1992 FY | 82.4 Million USD | 20.82% |
| 1992 Q2 | 20 Million USD | 10.5% |
| 1992 Q3 | 21.9 Million USD | 9.5% |
| 1991 Q4 | 18.4 Million USD | 8.88% |
| 1991 FY | 68.2 Million USD | -6.32% |
| 1991 Q1 | 16.8 Million USD | -3.45% |
| 1991 Q2 | 16 Million USD | -4.76% |
| 1991 Q3 | 16.9 Million USD | 5.63% |
| 1990 FY | 72.8 Million USD | 22.97% |
| 1990 Q4 | 17.4 Million USD | -3.87% |
| 1990 Q3 | 18.1 Million USD | -7.18% |
| 1990 Q2 | 19.5 Million USD | 9.55% |
| 1990 Q1 | 17.8 Million USD | 9.2% |
| 1989 Q4 | 16.3 Million USD | 7.95% |
| 1989 FY | 59.2 Million USD | 25.16% |
| 1989 Q1 | 13.6 Million USD | 20.35% |
| 1989 Q3 | 15.1 Million USD | 6.34% |
| 1989 Q2 | 14.2 Million USD | 4.41% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| AbCellera Biologics Inc. | 38.02 Million USD | 80.594% |
| Alkermes plc | 1.66 Billion USD | 99.556% |
| Agenus Inc. | 156.31 Million USD | 95.279% |
| Aptorum Group Limited | 431.37 Thousand USD | -1610.565% |
| Ardelyx, Inc. | 124.45 Million USD | 94.071% |
| Dyadic International, Inc. | 2.89 Million USD | -154.553% |
| Eton Pharmaceuticals, Inc. | 31.64 Million USD | 76.68% |
| Lantern Pharma Inc. | - USD | -Infinity% |
| Inhibikase Therapeutics, Inc. | 260.5 Thousand USD | -2732.63% |
| Novavax, Inc. | 983.7 Million USD | 99.25% |
| Janux Therapeutics, Inc. | 8.08 Million USD | 8.71% |
| Pyxis Oncology, Inc. | - USD | -Infinity% |
| TransCode Therapeutics, Inc. | - USD | -Infinity% |
| Ocuphire Pharma, Inc. | 19.04 Million USD | 61.263% |
| Outlook Therapeutics, Inc. | - USD | -Infinity% |
| Madrigal Pharmaceuticals, Inc. | - USD | -Infinity% |
| Reviva Pharmaceuticals Holdings, Inc. | - USD | -Infinity% |
| SELLAS Life Sciences Group, Inc. | - USD | -Infinity% |
| Syros Pharmaceuticals, Inc. | 9.93 Million USD | 25.735% |
| Barinthus Biotherapeutics plc | 802 Thousand USD | -820.075% |
| Windtree Therapeutics, Inc. | - USD | -Infinity% |
| Xeris Biopharma Holdings, Inc. | 163.91 Million USD | 95.498% |
| Clearside Biomedical, Inc. | 8.22 Million USD | 10.297% |
| C4 Therapeutics, Inc. | 20.75 Million USD | 64.449% |
| Alnylam Pharmaceuticals, Inc. | 1.82 Billion USD | 99.596% |
| AlloVir, Inc. | - USD | -Infinity% |
| Arrowhead Pharmaceuticals, Inc. | 240.73 Million USD | 96.935% |
| VYNE Therapeutics Inc. | 424 Thousand USD | -1640.33% |
| Bicycle Therapeutics plc | 26.97 Million USD | 72.646% |
| BioXcel Therapeutics, Inc. | 1.38 Million USD | -434.71% |
| ChromaDex Corporation | 83.57 Million USD | 91.17% |
| Chimerix, Inc. | 324 Thousand USD | -2177.469% |
| Corbus Pharmaceuticals Holdings, Inc. | - USD | -Infinity% |
| Caribou Biosciences, Inc. | 34.47 Million USD | 78.597% |
| CRISPR Therapeutics AG | 371.2 Million USD | 98.012% |
| Precision BioSciences, Inc. | 48.72 Million USD | 84.856% |
| Fate Therapeutics, Inc. | 63.53 Million USD | 88.386% |
| Fortress Biotech, Inc. | 84.51 Million USD | 91.269% |
| Fortress Biotech, Inc. | 84.51 Million USD | 91.269% |
| HOOKIPA Pharma Inc. | 20.12 Million USD | 63.341% |
| ImmuCell Corporation | 17.47 Million USD | 57.766% |
| IDEAYA Biosciences, Inc. | 23.38 Million USD | 68.446% |
| Immix Biopharma, Inc. | - USD | -Infinity% |
| Incyte Corporation | 3.69 Billion USD | 99.8% |
| Innoviva, Inc. | 310.46 Million USD | 97.623% |
| IO Biotech, Inc. | - USD | -Infinity% |
| Jaguar Health, Inc. | 9.76 Million USD | 24.403% |
| Keros Therapeutics, Inc. | 151 Thousand USD | -4786.755% |
| Ligand Pharmaceuticals Incorporated | 131.31 Million USD | 94.381% |
| ContextLogic Inc. | 287 Million USD | 97.429% |
| MiMedx Group, Inc. | 321.47 Million USD | 97.705% |
| MEI Pharma, Inc. | 65.29 Million USD | 88.699% |
| NextCure, Inc. | - USD | -Infinity% |
| Onconetix, Inc. | 58.46 Thousand USD | -12521.226% |
| Oncternal Therapeutics, Inc. | 785 Thousand USD | -840.0% |
| Opthea Limited | 261.85 Thousand USD | -2717.929% |
| Psyence Biomedical Ltd. | - USD | -Infinity% |
| Vaxcyte, Inc. | - USD | -Infinity% |
| PDS Biotechnology Corporation | - USD | -Infinity% |
| Precigen, Inc. | 6.22 Million USD | -18.538% |
| Pharming Group N.V. | 245.31 Million USD | 96.992% |
| Phathom Pharmaceuticals, Inc. | 682 Thousand USD | -981.965% |
| Pieris Pharmaceuticals, Inc. | 42.81 Million USD | 82.763% |
| PureTech Health plc | 3.33 Million USD | -121.592% |
| Rigel Pharmaceuticals, Inc. | 116.88 Million USD | 93.687% |
| Avidity Biosciences, Inc. | 9.56 Million USD | 22.814% |
| Reviva Pharmaceuticals Holdings, Inc. | - USD | -Infinity% |
| Sangamo Therapeutics, Inc. | 176.23 Million USD | 95.813% |
| Sol-Gel Technologies Ltd. | 1.55 Million USD | -374.839% |
| Acelyrin, Inc. | - USD | -Infinity% |
| Salarius Pharmaceuticals, Inc. | - USD | -Infinity% |
| Summit Therapeutics Inc. | - USD | -Infinity% |
| Sensei Biotherapeutics, Inc. | - USD | -Infinity% |
| Senti Biosciences, Inc. | 2.56 Million USD | -188.13% |
| Stoke Therapeutics, Inc. | 8.78 Million USD | 15.957% |
| Elevation Oncology, Inc. | - USD | -Infinity% |
| Alaunos Therapeutics, Inc. | 5000.00 USD | -147480.0% |
| Telomir Pharmaceuticals, Inc. Common Stock | - USD | -Infinity% |
| Entrada Therapeutics, Inc. | 129.01 Million USD | 94.28% |
| VistaGen Therapeutics, Inc. | 1.06 Million USD | -593.515% |
| Kintara Therapeutics, Inc. | - USD | -Infinity% |
| Wave Life Sciences Ltd. | 113.3 Million USD | 93.487% |
| Seer, Inc. | 15.18 Million USD | 51.396% |
| Verrica Pharmaceuticals Inc. | 5.12 Million USD | -44.009% |
| Aadi Bioscience, Inc. | 24.35 Million USD | 69.701% |
| ESSA Pharma Inc. | - USD | -Infinity% |
| GlycoMimetics, Inc. | 10 Thousand USD | -73690.0% |
| GT Biopharma, Inc. | - USD | -Infinity% |
| Inhibrx Biosciences, Inc. | 1.8 Million USD | -309.944% |
| Akebia Therapeutics, Inc. | 194.62 Million USD | 96.209% |
| Catalyst Pharmaceuticals, Inc. | 398.2 Million USD | 98.147% |
| Longboard Pharmaceuticals, Inc. | - USD | -Infinity% |
| Orchestra BioMed Holdings, Inc. | 2.76 Million USD | -167.355% |
| Alzamend Neuro, Inc. | - USD | -Infinity% |
| Sorrento Therapeutics, Inc. | 62.83 Million USD | 88.257% |
| TRACON Pharmaceuticals, Inc. | 12.04 Million USD | 38.738% |
| Viracta Therapeutics, Inc. | - USD | -Infinity% |
| Rocket Pharmaceuticals, Inc. | - USD | -Infinity% |
| Aptose Biosciences Inc. | - USD | -Infinity% |
| ZyVersa Therapeutics, Inc. | - USD | -Infinity% |
| Soligenix, Inc. | 839.35 Thousand USD | -779.123% |
| Century Therapeutics, Inc. | 2.23 Million USD | -230.157% |
| Kura Oncology, Inc. | - USD | -Infinity% |
| TScan Therapeutics, Inc. | 21.04 Million USD | 64.944% |
| Intensity Therapeutics, Inc. | - USD | -Infinity% |
| Ocean Biomedical, Inc. | - USD | -Infinity% |
| CytomX Therapeutics, Inc. | 101.21 Million USD | 92.71% |
| Autolus Therapeutics plc | 1.69 Million USD | -334.57% |
| Mineralys Therapeutics, Inc. | - USD | -Infinity% |
| EyePoint Pharmaceuticals, Inc. | 46.01 Million USD | 83.965% |
| Eterna Therapeutics Inc. | 68 Thousand USD | -10751.471% |
| Adaptive Biotechnologies Corporation | 170.27 Million USD | 95.666% |
| GRI Bio, Inc. | 21.76 Million USD | 66.1% |
| Xenetic Biosciences, Inc. | 2.53 Million USD | -190.513% |
| Tenaya Therapeutics, Inc. | - USD | -Infinity% |
| IGM Biosciences, Inc. | 2.13 Million USD | -246.432% |
| INmune Bio, Inc. | 155 Thousand USD | -4660.645% |
| Heron Therapeutics, Inc. | 127.04 Million USD | 94.192% |
| SAB Biotherapeutics, Inc. | 2.23 Million USD | -229.568% |
| Pasithea Therapeutics Corp. | - USD | -Infinity% |
| Entero Therapeutics, Inc. | - USD | -Infinity% |
| Milestone Pharmaceuticals Inc. | 1 Million USD | -637.9% |
| X4 Pharmaceuticals, Inc. | - USD | -Infinity% |
| Atara Biotherapeutics, Inc. | 8.57 Million USD | 13.927% |
| Coherus BioSciences, Inc. | 257.24 Million USD | 97.132% |
| Verastem, Inc. | - USD | -Infinity% |
| Abeona Therapeutics Inc. | 3.5 Million USD | -110.829% |
| Pliant Therapeutics, Inc. | 1.58 Million USD | -367.025% |
| Tonix Pharmaceuticals Holding Corp. | 7.76 Million USD | 5.008% |
| Histogen Inc. | 3.76 Million USD | -95.781% |
| Aprea Therapeutics, Inc. | 583.23 Thousand USD | -1165.193% |
| Surrozen, Inc. | - USD | -Infinity% |
| Organovo Holdings, Inc. | 109 Thousand USD | -6669.725% |
| Lixte Biotechnology Holdings, Inc. | - USD | -Infinity% |
| Ovid Therapeutics Inc. | 391.69 Thousand USD | -1783.864% |
| Panbela Therapeutics, Inc. | - USD | -Infinity% |
| CASI Pharmaceuticals, Inc. | 33.87 Million USD | 78.22% |
| Cadrenal Therapeutics, Inc. Common Stock | - USD | -Infinity% |
| Centessa Pharmaceuticals plc | 6.85 Million USD | -7.675% |
| Hepion Pharmaceuticals, Inc. | - USD | -Infinity% |
| Arcturus Therapeutics Holdings Inc. | 157.74 Million USD | 95.322% |
| BioRestorative Therapies, Inc. | 145.8 Thousand USD | -4961.043% |
| Apollomics, Inc. | 821 Thousand USD | -798.782% |
| Amarin Corporation plc | 306.91 Million USD | 97.596% |
| Mesoblast Limited | 5.9 Million USD | -25.025% |
| Turnstone Biologics Corp. | 19.3 Million USD | 61.779% |
| Kymera Therapeutics, Inc. | 78.59 Million USD | 90.611% |
| Synaptogenix, Inc. | - USD | -Infinity% |
| Tiziana Life Sciences Ltd | - USD | -Infinity% |
| Aurinia Pharmaceuticals Inc. | 175.51 Million USD | 95.796% |
| BriaCell Therapeutics Corp. | - USD | -Infinity% |
| Monopar Therapeutics Inc. | - USD | -Infinity% |
| Exelixis, Inc. | 1.83 Billion USD | 99.597% |
| Better Therapeutics, Inc. | - USD | -Infinity% |
| Nurix Therapeutics, Inc. | 76.98 Million USD | 90.415% |
| Apellis Pharmaceuticals, Inc. | 396.59 Million USD | 98.139% |
| NLS Pharmaceutics AG | - USD | -Infinity% |
| Dermata Therapeutics, Inc. | - USD | -Infinity% |
| Aridis Pharmaceuticals, Inc. | - USD | -Infinity% |
| Gritstone bio, Inc. | 1.33 Million USD | -454.395% |
| Jasper Therapeutics, Inc. | - USD | -Infinity% |
| TNF Pharmaceuticals, Inc. | - USD | -Infinity% |
| Avid Bioservices, Inc. | 139.91 Million USD | 94.726% |
| Insmed Incorporated | 305.2 Million USD | 97.582% |
| Virpax Pharmaceuticals, Inc. | - USD | -Infinity% |
| MediWound Ltd. | 18.68 Million USD | 60.511% |
| OmniAb, Inc. | 34.16 Million USD | 78.401% |
| Alector, Inc. | 97.06 Million USD | 92.398% |
| Seres Therapeutics, Inc. | 126.32 Million USD | 94.159% |
| Checkpoint Therapeutics, Inc. | 103 Thousand USD | -7064.078% |
| Zai Lab Limited | 266.71 Million USD | 97.233% |
| Revance Therapeutics, Inc. | 234.04 Million USD | 96.847% |
| Aura Biosciences, Inc. | - USD | -Infinity% |
| Lyell Immunopharma, Inc. | 130 Thousand USD | -5576.154% |
| Immunic, Inc. | - USD | -Infinity% |
| Tarsus Pharmaceuticals, Inc. | 17.44 Million USD | 57.706% |
| Veracyte, Inc. | 361.05 Million USD | 97.956% |
| InMed Pharmaceuticals Inc. | 4.59 Million USD | -60.492% |
| FibroGen, Inc. | 147.75 Million USD | 95.006% |
| SeaStar Medical Holding Corporation | - USD | -Infinity% |
| Adial Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sonnet BioTherapeutics Holdings, Inc. | 147.8 Thousand USD | -4892.389% |
| Jazz Pharmaceuticals plc | 3.83 Billion USD | 99.808% |
| Cyclacel Pharmaceuticals, Inc. | 420 Thousand USD | -1656.905% |
| Amylyx Pharmaceuticals, Inc. | 380.78 Million USD | 98.062% |
| TG Therapeutics, Inc. | 233.66 Million USD | 96.842% |
| Galecto, Inc. | - USD | -Infinity% |
| Calithera Biosciences, Inc. | - USD | -Infinity% |
| Fortrea Holdings Inc. | 3.1 Billion USD | 99.763% |
| KalVista Pharmaceuticals, Inc. | - USD | -Infinity% |
| Aptevo Therapeutics Inc. | - USD | -Infinity% |
| XBiotech Inc. | - USD | -Infinity% |
| Jasper Therapeutics, Inc. | - USD | -Infinity% |
| Lyra Therapeutics, Inc. | 1.55 Million USD | -373.62% |
| Foghorn Therapeutics Inc. | 34.15 Million USD | 78.396% |
| Y-mAbs Therapeutics, Inc. | 84.81 Million USD | 91.3% |
| Theravance Biopharma, Inc. | 57.42 Million USD | 87.15% |
| Ultragenyx Pharmaceutical Inc. | 434.24 Million USD | 98.301% |
| Metagenomi, Inc. Common Stock | 44.75 Million USD | 83.513% |
| Vaxxinity, Inc. | - USD | -Infinity% |
| BioCryst Pharmaceuticals, Inc. | 331.41 Million USD | 97.773% |
| Gain Therapeutics, Inc. | 55.18 Thousand USD | -13272.599% |
| Cartesian Therapeutics, Inc. | 26 Million USD | 71.624% |
| NexImmune, Inc. | - USD | -Infinity% |
| Creative Medical Technology Holdings, Inc. | 9000.00 USD | -81888.889% |
| Marker Therapeutics, Inc. | 3.31 Million USD | -122.854% |
| Regeneron Pharmaceuticals, Inc. | 13.11 Billion USD | 99.944% |
| Chemomab Therapeutics Ltd. | - USD | -Infinity% |
| Scopus BioPharma Inc. | - USD | -Infinity% |
| RAPT Therapeutics, Inc. | - USD | -Infinity% |
| Ainos, Inc. | 122.11 Thousand USD | -5942.813% |
| Pluri Inc. | 326 Thousand USD | -2163.497% |
| Prothena Corporation plc | 91.37 Million USD | 91.924% |
| Adaptimmune Therapeutics plc | 60.28 Million USD | 87.759% |
| Celularity Inc. | 22.77 Million USD | 67.595% |
| Rallybio Corporation | - USD | -Infinity% |
| Cue Biopharma, Inc. | 5.49 Million USD | -34.408% |
| MeiraGTx Holdings plc | 14.01 Million USD | 47.357% |
| Omeros Corporation | - USD | -Infinity% |
| Humacyte, Inc. | - USD | -Infinity% |
| Immunocore Holdings plc | 249.42 Million USD | 97.042% |
| Cocrystal Pharma, Inc. | - USD | -Infinity% |
| Cidara Therapeutics, Inc. | 63.9 Million USD | 88.453% |
| Blueprint Medicines Corporation | 249.38 Million USD | 97.041% |
| CalciMedica, Inc. | - USD | -Infinity% |
| Cabaletta Bio, Inc. | - USD | -Infinity% |
| Marinus Pharmaceuticals, Inc. | 30.98 Million USD | 76.188% |
| Scholar Rock Holding Corporation | - USD | -Infinity% |
| Sana Biotechnology, Inc. | - USD | -Infinity% |
| Pulmatrix, Inc. | 7.29 Million USD | -1.11% |
| Elicio Therapeutics, Inc. | - USD | -Infinity% |
| Vigil Neuroscience, Inc. | - USD | -Infinity% |
| Intellia Therapeutics, Inc. | 36.27 Million USD | 79.658% |
| Adlai Nortye Ltd. American Depositary Shares | 4.99 Million USD | -47.708% |
| Cytokinetics, Incorporated | 7.53 Million USD | 2.005% |
| Eloxx Pharmaceuticals, Inc. | - USD | -Infinity% |
| Nutriband Inc. | 2.08 Million USD | -253.856% |
| Protara Therapeutics, Inc. | - USD | -Infinity% |
| Vor Biopharma Inc. | - USD | -Infinity% |
| Roivant Sciences Ltd. | 124.79 Million USD | 94.087% |
| Evogene Ltd. | 5.64 Million USD | -30.833% |
| ProKidney Corp. | - USD | -Infinity% |
| Applied Therapeutics, Inc. | 9.99 Million USD | 26.158% |
| Hoth Therapeutics, Inc. | - USD | -Infinity% |
| BridgeBio Pharma, Inc. | 9.3 Million USD | 20.682% |
| CorMedix Inc. | - USD | -Infinity% |
| BioLineRx Ltd. | 4.8 Million USD | -53.729% |
| Tango Therapeutics, Inc. | 36.52 Million USD | 79.799% |
| Galectin Therapeutics Inc. | - USD | -Infinity% |
| Atai Life Sciences N.V. | 314 Thousand USD | -2250.0% |
| Renovaro Biosciences Inc. | - USD | -Infinity% |
| Aerovate Therapeutics, Inc. | - USD | -Infinity% |
| Zentalis Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sagimet Biosciences Inc. | 2 Million USD | -268.95% |
| MediciNova, Inc. | 1 Million USD | -637.9% |
| Praxis Precision Medicines, Inc. | 2.44 Million USD | -201.553% |
| Cardio Diagnostics Holdings, Inc. | 17.06 Thousand USD | -43140.551% |
| GeoVax Labs, Inc. | - USD | -Infinity% |
| Axsome Therapeutics, Inc. | 270.6 Million USD | 97.273% |
| Biomea Fusion, Inc. | - USD | -Infinity% |
| PTC Therapeutics, Inc. | 937.82 Million USD | 99.213% |
| Mereo BioPharma Group plc | 10 Million USD | 26.21% |
| Cullinan Oncology, Inc. | - USD | -Infinity% |
| Syndax Pharmaceuticals, Inc. | - USD | -Infinity% |
| Absci Corporation | 5.71 Million USD | -29.049% |
| NRx Pharmaceuticals, Inc. | - USD | -Infinity% |
| 4D Molecular Therapeutics, Inc. | 20.72 Million USD | 64.392% |
| Dyne Therapeutics, Inc. | - USD | -Infinity% |
| Kiniksa Pharmaceuticals, Ltd. | 270.25 Million USD | 97.27% |
| Ventyx Biosciences, Inc. | - USD | -Infinity% |
| Allakos Inc. | - USD | -Infinity% |
| Imunon, Inc. | - USD | -Infinity% |
| Fulcrum Therapeutics, Inc. | 2.8 Million USD | -163.066% |
| Corcept Therapeutics Incorporated | 482.37 Million USD | 98.47% |
| BioAtla, Inc. | - USD | -Infinity% |
| NLS Pharmaceutics AG | - USD | -Infinity% |
| Bio-Path Holdings, Inc. | - USD | -Infinity% |
| Allogene Therapeutics, Inc. | 95 Thousand USD | -7667.368% |
| Larimar Therapeutics, Inc. | - USD | -Infinity% |
| XOMA Corporation | 4.75 Million USD | -55.086% |
| Kezar Life Sciences, Inc. | 7 Million USD | -5.414% |
| Cara Therapeutics, Inc. | 20.96 Million USD | 64.808% |
| aTyr Pharma, Inc. | 353 Thousand USD | -1990.368% |
| Aligos Therapeutics, Inc. | 15.52 Million USD | 52.482% |
| Akero Therapeutics, Inc. | - USD | -Infinity% |
| Viridian Therapeutics, Inc. | 314 Thousand USD | -2250.0% |
| Eliem Therapeutics, Inc. | - USD | -Infinity% |
| EyeGate Pharmaceuticals, Inc. | 12.05 Thousand USD | -61090.812% |
| Akari Therapeutics, Plc | - USD | -Infinity% |
| Tevogen Bio Holdings Inc. | - USD | -Infinity% |
| Halozyme Therapeutics, Inc. | 829.25 Million USD | 99.11% |
| Lexaria Bioscience Corp. | 226.2 Thousand USD | -3162.042% |
| UroGen Pharma Ltd. | 82.71 Million USD | 91.079% |
| Sutro Biopharma, Inc. | 153.73 Million USD | 95.2% |
| ZIVO Bioscience, Inc. | 27.65 Thousand USD | -26587.161% |
| Orgenesis Inc. | 530 Thousand USD | -1292.264% |
| Entera Bio Ltd. | - USD | -Infinity% |
| GH Research PLC | - USD | -Infinity% |
| Lisata Therapeutics, Inc. | - USD | -Infinity% |
| Reneo Pharmaceuticals, Inc. | - USD | -Infinity% |
| Xencor, Inc. | 168.33 Million USD | 95.617% |
| 60 Degrees Pharmaceuticals, Inc. | 253.57 Thousand USD | -2810.01% |
| Replimune Group, Inc. | - USD | -Infinity% |
| Coeptis Therapeutics Holdings, Inc. | - USD | -Infinity% |
| Vanda Pharmaceuticals Inc. | 192.64 Million USD | 96.17% |
| Lexaria Bioscience Corp. | 226.2 Thousand USD | -3162.042% |
| Portage Biotech Inc. | - USD | -Infinity% |
| Cardio Diagnostics Holdings, Inc. | 17.06 Thousand USD | -43140.551% |
| Olema Pharmaceuticals, Inc. | - USD | -Infinity% |
| OncoCyte Corporation | 1.5 Million USD | -390.951% |
| Qualigen Therapeutics, Inc. | 5.2 Million USD | -41.774% |
| Processa Pharmaceuticals, Inc. | - USD | -Infinity% |
| Purple Biotech Ltd. | - USD | -Infinity% |
| CollPlant Biotechnologies Ltd. | 10.95 Million USD | 32.667% |
| scPharmaceuticals Inc. | 13.59 Million USD | 45.715% |
| ProMIS Neurosciences, Inc. | - USD | -Infinity% |
| HilleVax, Inc. | - USD | -Infinity% |
| NeuroSense Therapeutics Ltd. | - USD | -Infinity% |
| Tharimmune, Inc. | - USD | -Infinity% |
| Genprex, Inc. | - USD | -Infinity% |
| Neumora Therapeutics, Inc. Common Stock | - USD | -Infinity% |
| Atossa Therapeutics, Inc. | - USD | -Infinity% |
| XTL Biopharmaceuticals Ltd. | - USD | -Infinity% |
| Virios Therapeutics, Inc. | - USD | -Infinity% |
| OKYO Pharma Limited | - USD | -Infinity% |
| Savara Inc. | - USD | -Infinity% |
| Curis, Inc. | 10.02 Million USD | 26.379% |
| Daré Bioscience, Inc. | 2.8 Million USD | -162.796% |
| Carmell Therapeutics Corporation | - USD | -Infinity% |
| Titan Pharmaceuticals, Inc. | 184 Thousand USD | -3910.326% |
| Achieve Life Sciences, Inc. | - USD | -Infinity% |
| BeiGene, Ltd. | 2.45 Billion USD | 99.7% |
| Kiromic BioPharma, Inc. | - USD | -Infinity% |
| Revolution Medicines, Inc. Warrant | 11.58 Million USD | 36.278% |
| Protagonist Therapeutics, Inc. | 60 Million USD | 87.702% |
| Erasca, Inc. | - USD | -Infinity% |
| bluebird bio, Inc. | 29.49 Million USD | 74.984% |
| Protagenic Therapeutics, Inc. | - USD | -Infinity% |
| BioMarin Pharmaceutical Inc. | 2.41 Billion USD | 99.695% |
| DBV Technologies S.A. | 15.72 Million USD | 53.084% |
| Protagenic Therapeutics, Inc. | - USD | -Infinity% |
| Moderna, Inc. | 6.84 Billion USD | 99.892% |
| Vincerx Pharma, Inc. | - USD | -Infinity% |
| Fresh Tracks Therapeutics, Inc. | 8 Million USD | 7.832% |
| Molecular Templates, Inc. | 57.3 Million USD | 87.124% |
| Acrivon Therapeutics, Inc. Common Stock | - USD | -Infinity% |
| Travere Therapeutics, Inc. | 145.23 Million USD | 94.919% |
| Monte Rosa Therapeutics, Inc. | - USD | -Infinity% |
| Spruce Biosciences, Inc. | 10.08 Million USD | 26.861% |
| Celldex Therapeutics, Inc. | 6.88 Million USD | -7.206% |
| Cogent Biosciences, Inc. | - USD | -Infinity% |
| MacroGenics, Inc. | 58.74 Million USD | 87.44% |
| RenovoRx, Inc. | - USD | -Infinity% |
| Adicet Bio, Inc. | - USD | -Infinity% |
| Prime Medicine, Inc. | - USD | -Infinity% |
| Aditxt, Inc. | 645.17 Thousand USD | -1043.719% |
| Adagene Inc. | 18.11 Million USD | 59.258% |
| Estrella Immunopharma, Inc. | - USD | -Infinity% |
| Quantum-Si incorporated | 1.08 Million USD | -581.978% |
| Maravai LifeSciences Holdings, Inc. | 288.94 Million USD | 97.446% |
| Acurx Pharmaceuticals, Inc. | - USD | -Infinity% |
| Voyager Therapeutics, Inc. | 250 Million USD | 97.048% |
| SciSparc Ltd. | 2.87 Million USD | -156.304% |
| Vericel Corporation | 197.51 Million USD | 96.264% |
| Revelation Biosciences, Inc. | - USD | -Infinity% |
| Minerva Neurosciences, Inc. | - USD | -Infinity% |
| Generation Bio Co. | 5.9 Million USD | -24.983% |
| Astria Therapeutics, Inc. | - USD | -Infinity% |
| Black Diamond Therapeutics, Inc. | - USD | -Infinity% |
| Arcutis Biotherapeutics, Inc. | 59.6 Million USD | 87.62% |
| Invivyd, Inc. | - USD | -Infinity% |
| Relay Therapeutics, Inc. | 25.54 Million USD | 71.115% |
| Quoin Pharmaceuticals, Ltd. | - USD | -Infinity% |
| Spero Therapeutics, Inc. | 96.73 Million USD | 92.372% |
| Artelo Biosciences, Inc. | - USD | -Infinity% |
| 2seventy bio, Inc. | 100.38 Million USD | 92.649% |
| ADMA Biologics, Inc. | 258.21 Million USD | 97.142% |
| Clene Inc. | 654 Thousand USD | -1028.287% |
| Capricor Therapeutics, Inc. | 25.17 Million USD | 70.693% |
| Boundless Bio, Inc. Common Stock | - USD | -Infinity% |
| GeoVax Labs, Inc. | - USD | -Infinity% |
| Recursion Pharmaceuticals, Inc. | 44.57 Million USD | 83.446% |
| Citius Pharmaceuticals, Inc. | - USD | -Infinity% |
| Contineum Therapeutics, Inc. Class A Common Stock | 50 Million USD | 85.242% |
| Relmada Therapeutics, Inc. | - USD | -Infinity% |
| Finch Therapeutics Group, Inc. | 107 Thousand USD | -6796.262% |
| ALX Oncology Holdings Inc. | - USD | -Infinity% |
| Vir Biotechnology, Inc. | 86.18 Million USD | 91.438% |
| Evaxion Biotech A/S | 73.11 Thousand USD | -9992.734% |
| Ocular Therapeutix, Inc. | 58.44 Million USD | 87.374% |
| Verve Therapeutics, Inc. | 11.75 Million USD | 37.243% |
| Trevena, Inc. | 3.12 Million USD | -136.128% |
| Surrozen, Inc. | - USD | -Infinity% |
| Tyra Biosciences, Inc. | - USD | -Infinity% |
| Cingulate Inc. | - USD | -Infinity% |
| Galmed Pharmaceuticals Ltd. | - USD | -Infinity% |
| Unity Biotechnology, Inc. | - USD | -Infinity% |
| Tenax Therapeutics, Inc. | - USD | -Infinity% |
| Terns Pharmaceuticals, Inc. | - USD | -Infinity% |
| ACADIA Pharmaceuticals Inc. | 726.43 Million USD | 98.984% |
| Connect Biopharma Holdings Limited | - USD | -Infinity% |
| Clearmind Medicine Inc. | - USD | -Infinity% |
| Kronos Bio, Inc. | 6.28 Million USD | -17.351% |
| Bolt Biotherapeutics, Inc. | 7.87 Million USD | 6.31% |
| CERo Therapeutics Holdings, Inc. | - USD | -Infinity% |
| Viking Therapeutics, Inc. | - USD | -Infinity% |
| Statera Biopharma, Inc. | - USD | -Infinity% |
| ImmunityBio, Inc. | 622 Thousand USD | -1086.334% |
| Korro Bio, Inc. | - USD | -Infinity% |
| Kineta, Inc. | 5.44 Million USD | -35.594% |
| BioVie Inc. | - USD | -Infinity% |
| Codexis, Inc. | 70.14 Million USD | 89.48% |
| Celularity Inc. | 22.77 Million USD | 67.595% |
| Crinetics Pharmaceuticals, Inc. | 4.01 Million USD | -83.877% |
| Celcuity Inc. | - USD | -Infinity% |
| Virax Biolabs Group Limited | 156.41 Thousand USD | -4617.458% |
| Cibus, Inc. | 1.81 Million USD | -306.109% |
| Eledon Pharmaceuticals, Inc. | - USD | -Infinity% |
| eFFECTOR Therapeutics, Inc. | - USD | -Infinity% |
| IN8bio, Inc. | - USD | -Infinity% |
| Kodiak Sciences Inc. | - USD | -Infinity% |
| Annexon, Inc. | - USD | -Infinity% |
| Adverum Biotechnologies, Inc. | 3.6 Million USD | -104.972% |
| Assembly Biosciences, Inc. | 7.16 Million USD | -3.015% |
| Avalo Therapeutics, Inc. | 1.92 Million USD | -283.524% |
| Ionis Pharmaceuticals, Inc. | 787.64 Million USD | 99.063% |
| Eyenovia, Inc. | 3787.00 USD | -194750.805% |
| Puma Biotechnology, Inc. | 235.63 Million USD | 96.868% |
| Conduit Pharmaceuticals Inc. | - USD | -Infinity% |
| Xilio Therapeutics, Inc. | - USD | -Infinity% |
| Arcellx, Inc. | 110.31 Million USD | 93.311% |
| Cardiff Oncology, Inc. | 488 Thousand USD | -1412.09% |
| Enanta Pharmaceuticals, Inc. | 79.2 Million USD | 90.684% |
| Regulus Therapeutics Inc. | - USD | -Infinity% |
| Moolec Science SA | 905.04 Thousand USD | -715.315% |
| Acumen Pharmaceuticals, Inc. | - USD | -Infinity% |
| Geron Corporation | 237 Thousand USD | -3013.502% |
| LAVA Therapeutics N.V. | 6.76 Million USD | -9.012% |
| Royalty Pharma plc | 2.35 Billion USD | 99.687% |
| Atea Pharmaceuticals, Inc. | - USD | -Infinity% |
| Greenwich LifeSciences, Inc. | - USD | -Infinity% |
| TFF Pharmaceuticals, Inc. | 733.87 Thousand USD | -905.49% |
| Mersana Therapeutics, Inc. | 36.85 Million USD | 79.978% |
| Humacyte, Inc. | - USD | -Infinity% |
| Structure Therapeutics Inc. | - USD | -Infinity% |
| 89bio, Inc. | - USD | -Infinity% |
| PMV Pharmaceuticals, Inc. | - USD | -Infinity% |
| Avenue Therapeutics, Inc. | - USD | -Infinity% |
| Genelux Corporation | 170 Thousand USD | -4240.588% |
| Trevi Therapeutics, Inc. | - USD | -Infinity% |
| Lexicon Pharmaceuticals, Inc. | 1.2 Million USD | -512.874% |
| Notable Labs, Ltd. | 310 Thousand USD | -2280.323% |
| Liquidia Corporation | 17.48 Million USD | 57.805% |
| Mustang Bio, Inc. | - USD | -Infinity% |
| Immunovant, Inc. | - USD | -Infinity% |
| Quantum-Si incorporated | 1.08 Million USD | -581.978% |
| Arbutus Biopharma Corporation | 18.14 Million USD | 59.324% |
| DiaMedica Therapeutics Inc. | - USD | -Infinity% |
| Vera Therapeutics, Inc. | 1.86 Million USD | -296.294% |
| Acasti Pharma Inc. | - USD | -Infinity% |
| MiNK Therapeutics, Inc. | - USD | -Infinity% |
| Pasithea Therapeutics Corp. | - USD | -Infinity% |
| Xenon Pharmaceuticals Inc. | - USD | -Infinity% |
| Elevai Labs, Inc. Common Stock | 1.71 Million USD | -330.867% |
| NeuroBo Pharmaceuticals, Inc. | - USD | -Infinity% |
| Tempest Therapeutics, Inc. | - USD | -Infinity% |
| Soleno Therapeutics, Inc. | - USD | -Infinity% |
| PepGen Inc. | - USD | -Infinity% |
| Moleculin Biotech, Inc. | - USD | -Infinity% |
| United Therapeutics Corporation | 2.32 Billion USD | 99.683% |
| Nuvectis Pharma, Inc. | - USD | -Infinity% |
| Solid Biosciences Inc. | - USD | -Infinity% |
| BriaCell Therapeutics Corp. | - USD | -Infinity% |
| Immuneering Corporation | - USD | -Infinity% |
| Lixte Biotechnology Holdings, Inc. | - USD | -Infinity% |
| Silo Pharma, Inc. | 72.1 Thousand USD | -10134.113% |
| Belite Bio, Inc | - USD | -Infinity% |
| XOMA Corporation | 4.75 Million USD | -55.086% |
| ARS Pharmaceuticals, Inc. | 30 Thousand USD | -24496.667% |
| Bionomics Limited | - USD | -Infinity% |
| Apogee Therapeutics, Inc. | - USD | -Infinity% |
| Alpha Tau Medical Ltd. | - USD | -Infinity% |
| uniQure N.V. | 15.84 Million USD | 53.424% |
| Cassava Sciences, Inc. | - USD | -Infinity% |
| Estrella Immunopharma, Inc. | - USD | -Infinity% |
| Poseida Therapeutics, Inc. | 64.7 Million USD | 88.596% |
| Forte Biosciences, Inc. | - USD | -Infinity% |
| Anebulo Pharmaceuticals, Inc. | - USD | -Infinity% |
| Enlivex Therapeutics Ltd. | - USD | -Infinity% |
| Conduit Pharmaceuticals Inc. | - USD | -Infinity% |
| SeaStar Medical Holding Corporation | - USD | -Infinity% |
| FibroBiologics, Inc. Common Stock | - USD | -Infinity% |
| Altimmune, Inc. | 426 Thousand USD | -1632.16% |
| Amicus Therapeutics, Inc. | 399.35 Million USD | 98.152% |
| Alpha Tau Medical Ltd. | - USD | -Infinity% |
| Compugen Ltd. | 33.45 Million USD | 77.946% |
| Peak Bio, Inc. | 367.87 Thousand USD | -1905.833% |
| Zevra Therapeutics, Inc. | 27.46 Million USD | 73.129% |
| Benitec Biopharma Inc. | 216 Thousand USD | -3316.204% |
| Spyre Therapeutics, Inc. | 886 Thousand USD | -732.844% |
| NKGen Biotech, Inc. Common Stock | - USD | -Infinity% |
| Zura Bio Limited | - USD | -Infinity% |
| PolyPid Ltd. | - USD | -Infinity% |
| Aileron Therapeutics, Inc. | - USD | -Infinity% |
| NKGen Biotech, Inc. Warrants | - USD | -Infinity% |
| Instil Bio, Inc. | - USD | -Infinity% |
| argenx SE | 1.22 Billion USD | 99.398% |
| Immunome, Inc. | 14.01 Million USD | 47.361% |
| Compass Therapeutics, Inc. | - USD | -Infinity% |
| Verona Pharma plc | - USD | -Infinity% |
| enGene Holdings Inc. Warrants | - USD | -Infinity% |
| Shattuck Labs, Inc. | 1.65 Million USD | -345.323% |
| CervoMed Inc. | 7.14 Million USD | -3.277% |
| LENZ Therapeutics, Inc. | - USD | -Infinity% |
| Plus Therapeutics, Inc. | 4.91 Million USD | -50.193% |
| Dianthus Therapeutics, Inc. | 2.82 Million USD | -161.111% |
| Moolec Science SA | 905.04 Thousand USD | -715.315% |
| Enveric Biosciences, Inc. | - USD | -Infinity% |
| Inovio Pharmaceuticals, Inc. | 832.01 Thousand USD | -786.888% |
| AnaptysBio, Inc. | 17.15 Million USD | 56.991% |
| Design Therapeutics, Inc. | - USD | -Infinity% |
| Leap Therapeutics, Inc. | - USD | -Infinity% |
| NeurAxis, Inc. | 2.46 Million USD | -199.953% |
| Seelos Therapeutics, Inc. | 2.2 Million USD | -234.952% |
| Lumos Pharma, Inc. | 2.05 Million USD | -259.776% |
| Achilles Therapeutics plc | - USD | -Infinity% |
| enGene Holdings Inc. Common Stock | - USD | -Infinity% |
| 180 Life Sciences Corp. | - USD | -Infinity% |
| Opiant Pharmaceuticals, Inc. | 40.72 Million USD | 81.881% |
| CERo Therapeutics Holdings, Inc. | - USD | -Infinity% |
| Nutriband Inc. | 2.08 Million USD | -253.856% |
| ORIC Pharmaceuticals, Inc. | - USD | -Infinity% |
| CG Oncology, Inc. Common stock | 204 Thousand USD | -3517.157% |
| Fractyl Health, Inc. Common Stock | 120 Thousand USD | -6049.167% |
| Rani Therapeutics Holdings, Inc. | - USD | -Infinity% |
| MoonLake Immunotherapeutics | - USD | -Infinity% |
| Palisade Bio, Inc. | 250 Thousand USD | -2851.6% |
| Tourmaline Bio, Inc. | - USD | -Infinity% |
| Beam Therapeutics Inc. | 377.7 Million USD | 98.046% |
| Neurogene Inc. | - USD | -Infinity% |
| Mirum Pharmaceuticals, Inc. | 186.37 Million USD | 96.041% |
| AEON Biopharma, Inc. | - USD | -Infinity% |
| CARGO Therapeutics, Inc. Common Stock | - USD | -Infinity% |
| Sesen Bio, Inc. | 40 Million USD | 81.553% |
| Enliven Therapeutics, Inc. | - USD | -Infinity% |
| Kiora Pharmaceuticals, Inc. | - USD | -Infinity% |
| Iovance Biotherapeutics, Inc. | 1.18 Million USD | -520.606% |
| Taysha Gene Therapies, Inc. | 15.45 Million USD | 52.243% |
| Athira Pharma, Inc. | - USD | -Infinity% |
| Vaccinex, Inc. | 570 Thousand USD | -1194.561% |
| HCW Biologics Inc. | 2.84 Million USD | -159.66% |
| XOMA Corporation | 4.75 Million USD | -55.086% |
| Nektar Therapeutics | 90.12 Million USD | 91.812% |
| Arvinas, Inc. | 78.5 Million USD | 90.6% |
| Tevogen Bio Holdings Inc. | - USD | -Infinity% |
| Merus N.V. | 43.94 Million USD | 83.209% |
| Omega Therapeutics, Inc. | 3.09 Million USD | -138.494% |
| Quince Therapeutics, Inc. | - USD | -Infinity% |
| Rezolute, Inc. | - USD | -Infinity% |
| Clene Inc. | 654 Thousand USD | -1028.287% |
| Indaptus Therapeutics, Inc. | - USD | -Infinity% |
| BeyondSpring Inc. | 1.75 Million USD | -321.416% |
| Synlogic, Inc. | 3.37 Million USD | -118.896% |
| Allarity Therapeutics, Inc. | - USD | -Infinity% |
| Phio Pharmaceuticals Corp. | - USD | -Infinity% |
| Peak Bio, Inc. | 367.87 Thousand USD | -1905.833% |
| Werewolf Therapeutics, Inc. | 19.94 Million USD | 63.0% |
| Krystal Biotech, Inc. | 50.69 Million USD | 85.445% |
| Karyopharm Therapeutics Inc. | 146.03 Million USD | 94.947% |
| SpringWorks Therapeutics, Inc. | 5.44 Million USD | -35.469% |
| Lipella Pharmaceuticals Inc. | 449.61 Thousand USD | -1541.175% |
| MannKind Corporation | 198.96 Million USD | 96.291% |
| Ikena Oncology, Inc. | 9.16 Million USD | 19.443% |
| Cyclerion Therapeutics, Inc. | - USD | -Infinity% |
| Gyre Therapeutics, Inc. | 113.45 Million USD | 93.496% |
| Gossamer Bio, Inc. | - USD | -Infinity% |
| CohBar, Inc. | - USD | -Infinity% |
| Cognition Therapeutics, Inc. | - USD | -Infinity% |
| NRx Pharmaceuticals, Inc. | - USD | -Infinity% |
| Legend Biotech Corporation | 285.14 Million USD | 97.412% |
| Mural Oncology plc | - USD | -Infinity% |
| Biora Therapeutics, Inc. | 4000.00 USD | -184375.0% |
| PaxMedica, Inc. Common Stock | - USD | -Infinity% |
| Disc Medicine, Inc. | - USD | -Infinity% |
| Champions Oncology, Inc. | 50.15 Million USD | 85.288% |
| REGENXBIO Inc. | 90.24 Million USD | 91.823% |
| Ensysce Biosciences, Inc. | 2.23 Million USD | -230.82% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| Cellectar Biosciences, Inc. | - USD | -Infinity% |
| Edgewise Therapeutics, Inc. | - USD | -Infinity% |
| PharmaCyte Biotech, Inc. | - USD | -Infinity% |
| Aldeyra Therapeutics, Inc. | - USD | -Infinity% |
| Cellectis S.A. | 755 Thousand USD | -877.351% |
| Longeveron Inc. | 709 Thousand USD | -940.762% |
| Repare Therapeutics Inc. | 51.13 Million USD | 85.569% |
| Sarepta Therapeutics, Inc. | 1.24 Billion USD | 99.407% |
| Inozyme Pharma, Inc. | - USD | -Infinity% |
| Revolution Medicines, Inc. | 11.58 Million USD | 36.278% |
| Nymox Pharmaceutical Corporation | - USD | -Infinity% |
| Third Harmonic Bio, Inc. | - USD | -Infinity% |
| ArriVent BioPharma, Inc. Common Stock | - USD | -Infinity% |
| AN2 Therapeutics, Inc. | - USD | -Infinity% |
| Anixa Biosciences, Inc. | 210 Thousand USD | -3413.81% |
| Vertex Pharmaceuticals Incorporated | 9.86 Billion USD | 99.925% |
| Denali Therapeutics Inc. | 330.53 Million USD | 97.768% |
| Revelation Biosciences, Inc. | - USD | -Infinity% |
| Veru Inc. | 16.29 Million USD | 54.722% |
| Corvus Pharmaceuticals, Inc. | - USD | -Infinity% |
| Cingulate Inc. | - USD | -Infinity% |
| Passage Bio, Inc. | - USD | -Infinity% |
| Context Therapeutics Inc. | - USD | -Infinity% |
| Exicure, Inc. | - USD | -Infinity% |
| Day One Biopharmaceuticals, Inc. | - USD | -Infinity% |
| Oramed Pharmaceuticals Inc. | 2.7 Million USD | -172.993% |
| Scinai Immunotherapeutics Ltd. | - USD | -Infinity% |
| Rhythm Pharmaceuticals, Inc. | 77.42 Million USD | 90.47% |
| Nuvalent, Inc. | - USD | -Infinity% |
| ABVC BioPharma, Inc. | 152.43 Thousand USD | -4740.911% |
| Carisma Therapeutics, Inc. | 14.91 Million USD | 50.54% |
| Unicycive Therapeutics, Inc. | 675 Thousand USD | -993.185% |
| OmniAb, Inc. | 34.16 Million USD | 78.401% |
| Anew Medical, Inc. | - USD | -Infinity% |
| Fennec Pharmaceuticals Inc. | 21.25 Million USD | 65.279% |
| Lipocine Inc. | -2.85 Million USD | 358.838% |
| Lexeo Therapeutics, Inc. Common Stock | - USD | -Infinity% |
| Nautilus Biotechnology, Inc. | - USD | -Infinity% |
| SAB Biotherapeutics, Inc. | 2.23 Million USD | -229.568% |
| G1 Therapeutics, Inc. | 82.51 Million USD | 91.057% |
| Bellerophon Therapeutics, Inc. | - USD | -Infinity% |
| Sage Therapeutics, Inc. | 86.45 Million USD | 91.465% |
| Ocugen, Inc. | 6.03 Million USD | -22.25% |
| Mind Medicine (MindMed) Inc. | - USD | -Infinity% |
| Q32 Bio Inc. | 1.15 Million USD | -538.322% |
| Brainstorm Cell Therapeutics Inc. | - USD | -Infinity% |
| Alumis Inc. Common Stock | - USD | -Infinity% |
| Equillium, Inc. | 36.08 Million USD | 79.55% |
| Kyverna Therapeutics, Inc. | - USD | -Infinity% |
| Coya Therapeutics, Inc. | 6 Million USD | -22.938% |
| CNS Pharmaceuticals, Inc. | - USD | -Infinity% |
| Galera Therapeutics, Inc. | - USD | -Infinity% |
| Evelo Biosciences, Inc. | - USD | -Infinity% |
| Comera Life Sciences Holdings, Inc. | 633.1 Thousand USD | -1065.531% |
| Dominari Holdings Inc. | 2.03 Million USD | -261.893% |
| Edesa Biotech, Inc. | - USD | -Infinity% |
| vTv Therapeutics Inc. | - USD | -Infinity% |
| Bio-Techne Corporation | 1.15 Billion USD | 99.363% |
| Agios Pharmaceuticals, Inc. | 26.82 Million USD | 72.49% |
| Harmony Biosciences Holdings, Inc. | 582.02 Million USD | 98.732% |
| Prelude Therapeutics Incorporated | - USD | -Infinity% |
| Candel Therapeutics, Inc. | - USD | -Infinity% |
| iTeos Therapeutics, Inc. | 12.59 Million USD | 41.413% |
| Nkarta, Inc. | - USD | -Infinity% |
| BioCardia, Inc. | 477 Thousand USD | -1446.96% |
| Iterum Therapeutics plc | - USD | -Infinity% |